<HTML>
 <HEAD>
 <!-- $MVD$:app("MicroVision WebExpress") -->
 <TITLE>4168i02</TITLE><!-- $MVD$:template("","0","0") -->
 <!-- $MVD$:fontset("Symbol","Symbol") -->
 <META NAME="GENERATOR" CONTENT="MicroVision Development / WebExpress">
 </HEAD>
 <BODY BGCOLOR=#FFFFFF>
 <P ALIGN=CENTER>
 <CENTER><img src="http:/img/fbpe/bjmbr/v34n11/4168i02.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></CENTER>
 </P><P>
 Figure 2. <I>A</I> and <I>B</I>, Scatter plots of the relationship between the best-estimated AUC<SUB>0-</SUB><!-- $MVD$:face("Symbol") --><FONT FACE="Symbol"><SUB>&#165;</SUB></FONT> (&#181;g h<BR>
 ml<SUP>-1</SUP>) of 4-methylaminoantipyrine (MAA; abscissa) and the AUC<SUB>0-</SUB><!-- $MVD$:face("Symbol") --><FONT FACE="Symbol"><SUB>&#165;</SUB></FONT> derived from the 2-point limited-sampling strategy (LSS) models for each volunteer (ordinate), using the jack-knife approach (Methods). <I>Panel A</I>, Formulation A, data for 5 and 24 h. <I>Panel B</I>, Formulation B, data for 4 and 24 h. <I>C</I>, Scatter plot of the relationship between the best-estimated AUC<SUB>0-</SUB><!-- $MVD$:face("Symbol") --><FONT FACE="Symbol"><SUB>&#165;</SUB></FONT> (&#181;g h ml<SUP>-1</SUP>) of MAA for dipyrone formulation A (abscissa) and the AUC<SUB>0-</SUB><!-- $MVD$:face("Symbol") --><FONT FACE="Symbol"><SUB>&#165;</SUB></FONT> derived using the 2-point LSS model developed for formulation B and the concentrations observed at the same respective times, but after administration of formulation A (ordinate). The continuous line in each plot represents the line of identity between the LSS-derived and the best-estimated AUC<SUB>0-</SUB><!-- $MVD$:face("Symbol") --><FONT FACE="Symbol"><SUB>&#165;</SUB></FONT>. AUC<SUB>0-</SUB><!-- $MVD$:face("Symbol") --><FONT FACE="Symbol"><SUB>&#165;</SUB></FONT><SUB> </SUB>= area under the plasma drug concentration versus time curve from 0 to infinity.</BODY>
</HTML>